1

1 Gene expression based molecular test proves clinical validity as diagnostic aid for the 2 differential diagnosis of psoriasis and eczema in formalin fixed and paraffin embedded 3 tissue 4 5 Authors: 6 Felix Fischer¹, Sophie Roenneberg², Larissa Graner⁴, Franziska Schlenker⁴, Roland Zengerle^{3,4}, Fabian J. Theis^{1,6}, Carsten B. Schmidt-Weber⁵, Tilo Biedermann², Felix Lauffer², 7 Natalie Garzorz-Stark² and Stefanie Eyerich^{5,*} 8 9 10 **Affiliations:** 11 ¹Institute of Computational Biology, Helmholtz Center Munich, Neuherberg, Germany 12 ²Department of Dermatology and Allergy, Technical University of Munich, Munich, 13 Germany 14 ³Laboratory for MEMS Applications, Department of Microsystems Engineering - IMTEK, 15 ⁴University of Freiburg, Freiburg, Germany, Hahn-Schickard Society for Applied Research, 16 Freiburg, Germany 17 ⁵ZAUM – Center of Allergy and Environment, Technical University of Munich and 18 Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Munich, 19 Germany 20 ⁶Department of Mathematics, Technical University of Munich, Garching, Germany 21 *To whom correspondence should be addressed: stefanie.eyerich@tum.de 22

2

23

24

25 Abstract

26

27 Highly specific and efficient drugs have been developed during the last two decades to treat 28 non-communicable chronic inflammatory skin diseases (ncISD). Due to their specificity, 29 these drugs are asking for precise diagnostic measures to attribute the most efficient treatment 30 to each patient. Diagnosis, however, is complicated by the complex pathogenesis of ncISD 31 and their clinical and histological overlap. Especially, precise diagnosis of psoriasis and 32 eczema is difficult in special cases and molecular diagnostic tools need to be developed to 33 support gold standard diagnosis of patients. In this line, we have developed a real-time based 34 molecular classifier to distinguish psoriasis from eczema in RNA-later fixed skin samples. 35 However, this type of skin sample is not regularly used in routine diagnostics. Therefore, we 36 evaluated if the combination of NOS2 and CCL27 expression in lesional skin can be 37 transferred to formalin-fixed paraffin embedded (FFPE) tissue. We present a FFPE-based 38 molecular classifier (MC) that determines the probability for psoriasis with a specificity and 39 sensitivity of 100% and 92%, respectively, and an area under the curve (AUC) of 0.97 40 delivering comparable results to the RNA-later based MC. The probability for psoriasis as 41 well as the PCR result of NOS2 expression correlated positive with disease hallmarks of 42 psoriasis and negative with eczema hallmarks. This tool now offers broad usage in pathology 43 laboratories and can support diagnostic decision making on a molecular level.

44

45 Key Words

46 Diagnostic aid; FFPE, NOS2; CCL27; inflammatory skin diseases; precision medicine

3

47

48

49 Introduction

50

51 Psoriasis and eczema are one of the most prevalent and relevant skin diseases worldwide with 52 an incidence rate for both diseases together of at least 2,000/100,000 (Bylund, von 53 Kobyletzki, Svalstedt, & Svensson, 2020; Thyssen, Johansen, Linneberg, & Menne, 2010; 54 Vena et al., 2010). Although more than a dozen of specific immune-modulating therapies 55 including biologicals and small molecules have been made available to treat patients more 56 efficiently than ever before over the last decade (Tizek et al., 2021), the ultimate breakthrough 57 has yet to arise due to missing accurate diagnostics tools. Diagnosis of both diseases largely 58 depends on a subjective visual exam and histopathological examination. Due to phenotypical 59 overlaps of both diseases up to 50 % of cases are misdiagnosed (Kolesnik, Franke, Lux, 60 Quist, & Gollnick, 2018). To close this important diagnostic gap, a gene expression based 61 classifier using NOS2 and CCL27 as marker genes has been proposed and its clinical validity 62 has been examined and proven in various patient cohorts (Bentz et al., 2021; Brunner et al., 63 2018; Garzorz-Stark et al., 2016; Quaranta et al., 2014; Stoffel et al., 2018). Renert-Yuval et 64 al. list the NOS/CCL27 classifier as the only accepted disease classifier for psoriasis and 65 eczema (Renert-Yuval et al., 2021). Here, we applied the molecular classifier in formalin-66 fixed paraffin embedded biopsy specimens of eczema and psoriasis to validate its clinical 67 utility as diagnostic aid in pathology laboratories (n=107). We demonstrated that the FFPE-68 based classifier delivered the correct clinical and histopathological diagnosis on the level of 69 RT-PCR with a test sensitivity and specificity of 92% and 100%, respectively. By opening 70 FFPE samples to molecular diagnostics, this FFPE-based classifier can now be used in routine 71 diagnostics and aid physician in their diagnostic decision making.

/		
	r	

72			
73			

75

74

76 Patients and material sampling

Material and Methods

77 FFPE samples for this retrospective study were derived from the Biobank Biederstein and 78 consisted of 107 patients (psoriasis, n=27; eczema, n=48, disease subtypes, n=18 and cases 79 with contradictory diagnosis n=14)). Final diagnosis of patients was determined by at least 80 two dermatologists taking a comprehensive view onto the clinical picture, family history, 81 laboratory parameters and histological assessment. Characteristics of all patients are shown in 82 Table 1. Patients treated with immune-efficient medication prior to material sampling were 83 excluded from the study. The study was approved by the local ethical committee (project 84 number 2773/10 and 515/17). Generated data and codes can be provided upon request.

85

86 Characteristics of FFPE tissue and isolation of total RNA

87 Skin biopsies (Ø3-6mm) from patients with a potential diagnosis of psoriasis or eczema were 88 taken under local anesthesia by a dermatologist and immediately fixed in neutral buffered 89 formalin for 8-48 hours at room temperature or 4°C. Fixed biopsies were paraffin embedded 90 according to standard procedures (one biopsy per paraffin cassette). Unstained FFPE skin 91 biopsies (<10 years of age) were used to isolate mRNA. Here, tissue sections with a thickness 92 of 10 µm were generated from each FFPE skin sample. The first sections containing both 93 epidermis and dermis were trimmed (at least 30µM) and discarded to avoid usage of degraded 94 material. mRNA was extracted from in total three FFPE sections using a magnetic bead-based

5

95	purification method according to the manufacturer's protocol (InnuPREP MP Basic FFPE
96	RNA Kit, IST Innuscreen, Germany). The mRNA eluates were analyzed immediately after
97	the extraction by real-time PCR using specifc primer and hydrolysis probes.
98	

99 Primer design and Real-time PCR

For specific amplification of the genes of interests *NOS2* and *CCL27* as well as of the reference genes, *TBP* and *SDHAF2*, primers and hydrolysis probes were designed using the primer design tool PrimerBLAST from NCBI (https://www.ncbi.nlm.nih.gov/tools/primerblast/). Oligonucleotides were synthesized by biomers (Germany). *P*robes were labeled with an Atto 647N fluorophore at the 5'-end and quenched with a BHQ2 quencher at the 3'-end.

105 Primer and probe sequences were as follows (forward, reverse and probe): 5'-106 TTCCTGGTTTGACTGTCCTTACC-3', 5'- T7TTCACTGTGGGGGCTTGC-3' and 5'-107 CGGGGAGGCAGTGCAGCCAGC-3' for NOS2; 5'- ACCCTACAGCAGCATTCCTAC-3', 108 5'-AGCTTGTCTGAGAGTGGCTTTC-3' 5'and 109 ACCCAGCACTGCCTGCTGTACTCAGCTC-3' for *CCL27*: 5'-110 ATGGATCAGAACAACAGCCTGC-3', 5'- CATTGGACTAAAGATAGGGATTCCG-3' 111 and 5'-TCAGGGCTTGGCCTCCCCTCAGGGTGCC-3' for TBP; 5'-112 CGGTGTCTACAGTGTTCTCGAC-3', 5'- GATGTCACACTGAGCAAAGGAG-3' and 5'-113 CGCTGATGCTTGCTCTGTCAAGGCACAGCC-3' for SDHAF2.

Real-time PCR reactions were carried out in 96-well plates using a Thermo Fisher Scientific one-step RT-PCR master mix. Thermocycling and fluorescence detection were performed in a qTower³ (Analytik Jena, Germany) and amplification results were analyzed using the qPCRsoft 4.1 software (Analytik Jena).

119 FFPE-based molecular classifier (MC) built-up

120 The molecular classifier was built using L2 regularized logistic regression. The molecular 121 classifier predicts the disease state (probability for psoriasis) directly from the normalized CT 122 values of NOS2 and CCL27 normalized to the reference genes SDHAF2 and TBP. For 123 classification the psoriasis and eczema subtypes are aggregated to their respective high level 124 The model was calculated using LinearRegression labels (eczema or psoriasis). 125 implementation from scikit-learn with an L2 regularization strength of 100. In addition, the 126 uncertainty of the model is estimated based on the predicted probability (cases with a 127 predicted probability between 45% and 55% are predicted as undetermined). The model was 128 trained on 77 patients with a clear diagnosis of psoriasis and eczema (atopic dermatitis (AD) 129 and nummular eczema (NE)) and achieved an AUC of 0.97 +/- 0.06 on the training data. 130 Furthermore, the model achieved a sensitivity = 91% and a specificity = 91% on the 131 evaluation set which includes the training data plus 18 additional patients with prediagnosed 132 subtypes of psoriasis and eczema.

133

134 Correlation of FFPE-based MC probability and PCR results with clinical attributes

Pearson correlation coefficients were calculated to determine the correlation between the FFPE-based MC determined probabilities for psoriasis, the negative delta CT PCR results of *CCL27* and *NOS2* as well as histological parameters, morphology of the lesion, comorbidities, laboratory parameters and family history.

139 **Results**

The FFPE-based molecular classifier (MC) precisely separates eczema from psoriasis and efficiently identifies subtypes of both diseases

142 To evaluate the potential of FFPE samples for molecular diagnostics, 76 FFPE samples of 143 lesional psoriasis (n=27) and eczema (atopic dermatitis n=28; nummular eczema n=21) were 144 analyzed by probe-based real-time PCR for the expression of NOS2 and CCL27. To calculate 145 a FFPE-based molecular classifier (MC) for differentiation of psoriasis and eczema, a logistic 146 regression model was fitted with a 5-times cross validation. This classifier was designed to 147 predict the probability of psoriasis with a cut-off value of 55% (The range between 45% and 148 55% would no probability (undetermined). Test specificity for psoriasis was 100% with a 149 sensitivity of 92% and an area under the ROC curve (AUC) of 0.97 +/- 0.06 (Fig. 1A). Two 150 psoriasis patients were mis-classified, and two further psoriasis patients reached a probability 151 between 45-55% and thereby could not be evaluated (Fig. 1B). In a next step, we used the 152 FFPE-based MC to classify subtypes of psoriasis (psoriasis guttata n=5; psoriasis 153 palmoplantaris n=1; generalized pustular psoriasis n=2; and psoriasis pustulosa 154 palmoplantaris n=3) and eczema (dishidrotic eczema n=4; hyperkeratotic rhagadiforme 155 eczema n=3) (Fig. 1B). Whereas all cases of psoriasis guttata, psoriasis palmoplantaris and 156 psoriasis pustulosa pampoplantaris were diagnosed correctly by the FFPE-based MC, cases of 157 dishidrotic and hyperkeratotic-rhagadiform eczema as well as generalized pustular psoriasis 158 tended to be misdiagnosed.

159

160 FFPE classifier results correlate with clinical attributes of psoriasis and eczema

161 To understand if the determined probability for psoriasis also correlates with clinical 162 attributes associated with psoriasis or eczema, Person correlation coefficients were

163 determined (Fig. 2). The probability of psoriasis highly and positively correlated with the 164 histological attributes 'dilated dermal capillaries' (r=0.61), 'acanthosis' (r=0.51), 'neutrophils' 165 (r=0.39) and 'parakeratosis' (r=0.33) (Fig. 2) – all hallmarks for the pathogenesis of psoriasis. 166 This positive correlation was followed by a positive correlation of negative CT values of 167 *NOS2* (r=.43; r=0.23; r=0.23; r=0.25, respectively) and a negative correlation with negative 168 delta CT values for CCL27 (r=-0.54; r=-0.5; r=-0.48; r=-0.22, respectively). In line, the 169 probability of psoriasis and the negative delta CT for NOS2 correlated positive with a 170 psoriasis type morphology (r=0.77 and r=0.56) and arthritis (r=0.34 and r=0.35), whereas a 171 negative correlation was determined for an eczema type morphology (r=-0.77 and r=-0.56) 172 and rhinoconjunctivitis allergica (RCA) (r=-0.47 and r=-0.28) (Fig. 2). The probability of 173 psoriasis also correlated positive with the therapeutic efficiency of IL12/IL-23 (r=0.99) and 174 TNF-a inhibition (r=0.56), however negative with the response to Fumarate (r=-0.34) of IL-17 175 inhibition (r=-0.74). No correlations of the laboratory parameters 'Stap.aureus' and specific 176 'IgE' as well as the family history of for psoriasis and eczema were identified.

177

The FFPE-based MC supports diagnostic decision making in patients with inconsistent diagnosis

180 To further evaluate the potential of the FFPE-based MC to support diagnostic decision 181 making, 14 patient samples with discrepant clinical and histological diagnosis were analyzed. 182 Within this cohort, 9 patients were assigned a probability for psoriasis and 5 patients were 183 classified as eczema (Fig. 3A). Patient 43, a close to 80 year old woman, developed shortly 184 after a respiratory infection itchy, pustular reddening overall the whole body. Bacterial or 185 viral infections were not detected. Extensive lesional skin at the thigh and knee were 186 surgically excised. Histologically, the lesions presented with infiltration of neutrophils and 187 isolated eosinophils, signs of spongiosis and in part parakeratosis. The patient was diagnosed

9

188 with psoriasis pustulosa, however, acute generalized exanthematic pustulosis (AGEP) could 189 not be ruled out. In fact, psoriasis pustulosa and AGEP can hardly be distinguished by 190 classical histological examination. Our FFPE-based MC assigned this patient a probability of 191 psoriasis of 74.49%. After initiation of Ixekizumab, the skin status of this patient improved 192 supporting the MC-based classification (Fig. 3B).

193 Patient 59, a mid-sixty male, presented in the clinic with reddish, hyperkeratotic, scaly and 194 itchy skin lesions at both palmae accompanied by erythematous, heavily infiltrated plaques at 195 the back, the capillitium and retroauricular. Histopathological examination showed 196 psoriasiform acanthosis, hyperparakeratosis, a lymphocytic infiltrate and isolated plasma cells 197 leading to the diagnosis of psoriasiform perivascular dermatitis, while clinically diagnostics 198 was in favor for psoriasis. The FFPE-based MC assigned a probability for psoriasis of 199 99.53%. Skin lesions at the palms and body cleared after 6 months of methothrexate therapy 200 (Fig. 3B).

201 Patient 62, a male at the end of his sixties, presented at the clinic with confluent, 202 erythematous, crude-lamellar, scaly plaques at both palmae. Histologically, extended 203 hyperparakeratosis, serum crusts, psoriasiforme epidermis hyperplasia combined with 204 spongiosis and a linear lymphocytic infiltrate in absence of neutrophils and eosinophils was 205 described leading to the diagnosis of hyperkeratotic, in part dyshidrotic hand eczema. The 206 FFPE-based MC assigned this patient a probability for psoriasis of 8.25% and thereby a high 207 likelihood of an underlying eczematous disease. Treatment with a topical corticosteroids and 208 altitretinoin improved the skin lesions supporting the MC-based classification (Fig. 3B).

Patient 75, a woman at beginning of her sixties, has been suffering for years under recurrent itchy, sharply demarcated erythematous plaques, with in part lamellar scales and excoriations as clinically seen in both psoriasis and eczema variants. Histologically, a psoriasiform hyperplasia of the epidermis combined with hyperparakeratosis, hypogranulosis, elongated rete-ridges, papillomatosis and focal spongiosis in upper epidermis layers was found. A

- 214 perivascular dense lymphocytic infiltrate with absence of neutrophils and eosinophils was
- 215 identified. The patient was diagnosed with a nummular eczema. This is supported also by the
- 216 FFPE-based MC that assigned a probability of 18.29% to this patient (Fig. 3B) and skin
- 217 lesions improved with topical corticosteroids and UVB phototherapy.
- 218
- 219
- 220

221 **Discussion**

222 The development of highly specific biologic drugs has revolutionized treatment options for 223 various diseases during the past two decades (Noda, Krueger, & Guttman-Yassky, 2015). 224 However, due to their specificity, these drugs are most efficient in only a small group of 225 diseases and patients calling for efficient diagnosis and subsequent assignment of each patient 226 to the most appropriate drug. Whereas molecular diagnostics have been already developed 227 and used for cancer diagnosis followed by decision making on treatment regimens, they are 228 not well established in the field of chronic inflammatory skin diseases, yet (Grazia, Penna, 229 Perotti, Anichini, & Tassi, 2014; Levine & Fisher, 2014; Usher-Smith, Emery, Kassianos, & 230 Walter, 2014). In previous work, we have developed a disease classifier to dissect psoriasis 231 from eczema based on the expression levels of NOS2 and CCL27 (Quaranta et al., 2014; 232 Garzorz-Stark et al., 2016). This classifier has been validated by several groups and found its 233 acceptance in the field (Bentz et al., 2021; Brunner et al., 2018; Stoffel et al., 2018). However, 234 it was established on RNA-later fixed skin that is regularly used in research, but not in clinics, 235 private practices and pathology laboratories. Within these institutions, skin samples usually 236 are formalin fixed and paraffin embedded (FFPE). This way of fixation allows long-term 237 storage of samples and optimal assessment of histological hallmarks, however, by cross-238 linking of proteins with RNA and RNA degradation due to the fixation procedure, RNA 239 isolation from FFPE samples can be challenging. Here, optimized protocols have been 240 developed to minimize side effects of the fixation method and now allow to use this sample 241 type for efficient diagnostics. Within this work, we have transferred the RNA-later molecular 242 classifier to FFPE samples and were able to retrieve comparable results. Whereas the RNA-243 later based MC dissected psoriasis from eczema with a specificity and sensitivity for psoriasis 244 of 100% and 97.7%, respectively and an AUC of 0.99, the FFPE-based classifier determined 245 probabilities for psoriasis with a specificity and sensitivity of 100% and 92%, respectively, 246 and an AUC of 0.97 (Garzorz-Stark et al., 2016). Whereas only two classical psoriasis

12

247 samples were not classified correctly by the FFPE-based MC, all atopic dermatitis and 248 nummular eczema cases were diagnosed precisely. The FFPE-based MC was also able to 249 predict the diagnosis of psoriasis subtypes, however, delivered conflicting results for 250 dyshidrotic and hyperkeratotic-rhagadiform eczema. Unfortunately, the cohort of these 251 subtypes was very small (4 and 3 cases, respectively) and data on treatment regimens and 252 therapeutic efficiency were not available. As these patients are difficult to diagnose by gold 253 standard diagnostics, further studies need to be undertaken to prove the efficiency of 254 molecular classification in this eczema subtype. In addition, and in line with previous 255 findings, the FFPE-based classifier probability highly correlated with disease hallmarks of 256 psoriasis, but not hallmarks of eczema (Garzorz-Stark et al., 2016). Therefore, the reliability 257 of the two markers, NOS2 and CCL27, has been shown now also in a FFPE tissue arguing for 258 implementation of this molecular diagnostic aid in clinical routine diagnostics and pathology 259 laboratories. Here, however, further efforts have to be undertaken to simplify and speed up 260 the labor- and cost-intensive purification of RNA from FFPE tissue. In addition, fully 261 automated systems need to be developed to be integrated into the processes in routine 262 diagnostic laboratories. 263 264 265

266

267 Acknowledgments

268 The authors thank Kerstin Weber for excellent technical support and the Biobank Biederstein

269 for patient samples. This work was supported by the Medical Valley Award.

271 References

- 272 Bentz, P., Eyerich, K., Weber, K., Kluge, L., Ofenloch, R., & Weisshaar, E. (2021). [Cohort study for
- 273 long-term follow-up of patients in whom the so-called "molecular classifier" is used to distinguish
- 274 eczema from psoriasis: Background and implementation]. Hautarzt, 72(4), 354-357.
- 275 doi:10.1007/s00105-021-04774-9
- 276 Brunner, P. M., Pavel, A. B., Khattri, S., Leonard, A., Malik, K., Rose, S., . . . Guttman-Yassky, E.
- 277 (2018). Baseline IL22 expression in atopic dermatitis patients stratifies tissue responses to
- 278 fezakinumab. J Allergy Clin Immunol. doi:10.1016/j.jaci.2018.07.028
- 279 Bylund, S., von Kobyletzki, L. B., Svalstedt, M., & Svensson, A. (2020). Prevalence and Incidence of
- 280 Atopic Dermatitis: A Systematic Review. Acta Derm Venereol, 100(12), adv00160.
 281 doi:10.2340/00015555-3510
- 282 Garzorz-Stark, N., Krause, L., Lauffer, F., Atenhan, A., Thomas, J., Stark, S. P., . . . Eyerich, K.
- (2016). A novel molecular disease classifier for psoriasis and eczema. Exp Dermatol, 25(10), 767-774.
 doi:10.1111/exd.13077
- 285 Grazia, G., Penna, I., Perotti, V., Anichini, A., & Tassi, E. (2014). Towards combinatorial targeted
- therapy in melanoma: from pre-clinical evidence to clinical application (review). Int J Oncol, 45(3),
- 287 929-949. doi:10.3892/ijo.2014.2491
- 288 Kolesnik, M., Franke, I., Lux, A., Quist, S. R., & Gollnick, H. P. (2018). Eczema in Psoriatico: An
- 289 Important Differential Diagnosis Between Chronic Allergic Contact Dermatitis and Psoriasis in
- Palmoplantar Localization. Acta Derm Venereol, 98(1), 50-58. doi:10.2340/00015555-2779
- 291 Levine, D., & Fisher, D. E. (2014). Current status of diagnostic and prognostic markers in melanoma.
- 292 Methods Mol Biol, 1102, 177-197. doi:10.1007/978-1-62703-727-3_11
- 293 Noda, S., Krueger, J. G., & Guttman-Yassky, E. (2015). The translational revolution and use of
- biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol, 135(2), 324-336.
- 295 doi:10.1016/j.jaci.2014.11.015

14

- 296 Quaranta, M., Knapp, B., Garzorz, N., Mattii, M., Pullabhatla, V., Pennino, D., . . . Eyerich, K. (2014).
- 297 Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and
- 298 eczema. Sci Transl Med, 6(244), 244ra290. doi:10.1126/scitranslmed.3008946
- 299 Renert-Yuval, Y., Thyssen, J. P., Bissonnette, R., Bieber, T., Kabashima, K., Hijnen, D., & Guttman-
- 300 Yassky, E. (2021). Biomarkers in atopic dermatitis-a review on behalf of the International Eczema
- 301 Council. J Allergy Clin Immunol, 147(4), 1174-1190 e1171. doi:10.1016/j.jaci.2021.01.013
- 302 Stoffel, E., Maier, H., Riedl, E., Bruggen, M. C., Reininger, B., Schaschinger, M., . . . Brunner, P. M.
- 303 (2018). Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1
- activation with some distinct immunological characteristics. Br J Dermatol, 178(5), 1151-1162.
- 305 doi:10.1111/bjd.16126
- 306 Thyssen, J. P., Johansen, J. D., Linneberg, A., & Menne, T. (2010). The epidemiology of hand eczema
- in the general population--prevalence and main findings. Contact Dermatitis, 62(2), 75-87.
- 308 doi:10.1111/j.1600-0536.2009.01669.x
- 309 Tizek, L., Schuster, B., Gebhardt, C., Reich, K., von Kiedrowski, R., Biedermann, T., . . . Garzorz-
- 310 Stark, N. (2021). Molecular diagnostics in dermatology: An online survey to study usage, obstacles
- 311 and requirements in Germany. J Dtsch Dermatol Ges. doi:10.1111/ddg.14659
- 312 Usher-Smith, J. A., Emery, J., Kassianos, A. P., & Walter, F. M. (2014). Risk prediction models for
- 313 melanoma: a systematic review. Cancer Epidemiol Biomarkers Prev, 23(8), 1450-1463.
 314 doi:10.1158/1055-9965.EPI-14-0295
- Vena, G. A., Altomare, G., Ayala, F., Berardesca, E., Calzavara-Pinton, P., Chimenti, S., . . . Cricelli,
 C. (2010). Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational
 study from a national primary care database. Eur J Dermatol, 20(5), 593-598.
 doi:10.1684/ejd.2010.1017
- 319

321

322 Tables

	n	age		n	age
psoriasis)pso) (n=27)			aopic dermatitis (r	=28)	
m	20	49.7±12.56	m	13	47.69±25.82
w	7	65.86±10.12	w	15	55.67±29.08
psoriasis guttata (PG) (n=5)			nummular eczema (n=21)		
m	2	36.5±5.5	m	10	62.6±15.32
w	3	40.23±3.86	w	11	72±14.25
generalized pustular psoriasis (GPP) (n=2)			dishidrotic eczema	(DHE) (n=4)	
m	1	55-60	m	1	70-75
w	1	25-30	w	3	55.67±19.29
psoriasis palmoplantaris (PP) (n=1)			hyperkeratotic-rhagadiform eczema (HRE) (n=3)		
w	1	40-45	m	1	60-65
psoriasis pustulosa palmoplantaris (PPP) (n=3)			w	2	70±21.21
m	2	42±9.9	unclear cases (n=1	4)	
w	1	45-50	m	8	56.86±13.36
			w	6	66±9.7

323

324 Table 1: Patient characteristics

16

326 Figures and figure legends



328 *Figure 1:* The FFPE-based Molecular classifier (MC) dissects clinically clear cases of 329 psoriasis and eczema and is also efficient in subtypes of both diseases.

330 A) The molecular classifier (MC) was trained on clear cases of eczema (atopic dermatitis (AD 331 n=28), nummular eczema (NE, n=21) and psoriasis (Pso, n=27) using a logistic regression 332 model with a 5-fold cross validation delivering the probability of psoriasis. CT values of NOS2 and CCL27 were normalized to the reference genes SDHAF2 and TBP. The graph 333 334 indicates the dissection of eczema and psoriasis samples exemplarily for normalization B) 335 FFPE-based MC determined probabilities for psoriasis in clear cases of atopic dermatitis 336 (AD), nummular eczema (NE) and psoriasis (Pso). The grey are between 45%-55% indicates 337 undetermined probabilities C) The FFPE-based MC was used to predict the probability for 338 psoriasis in subtypes of eczema and psoriasis (dyshidrotic eczema, DHE n=; hyperkeratotic-339 rhagadiform eczema, HRE n=; psoriasis guttata, PG n=5; psoriasis palmoplantaris, PP n=1); 340 generalized pustular psoriasis, GPP n=2; and psoriasis pustulosa palmplantaris, PPP n=2). A 341 probability between 45% and 55% was defined as not evaluable.

342

- 343
- 344

Fig. 2



345

Figure 2: The FFPE-based MC determined probability for psoriasis correlates with disease
 hallmarks.

348 The probability for psoriasis as well as the negative delta CT values for CCL27 and NOS2

349 were correlated with clinical attributes by Pearson correlation.



350

351 *Figure 3:* The FFPE-based MC is able to support diagnosis of unclear cases.

A) The FFPE-based MC was applied on clinically and histologically challenging cases of patients with a suspected diagnosis of psoriasis or eczema and subtypes of both diseases (n=14). Given patient numbers represent numerical numbering and not biobank IDs. B) Clinical pictures and histological H&E stainings of selected patients that were assigned a

356 probability of psoriasis by the FFPE-based MC.